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The immune reconstitution inflammatory syndrome (IRIS) in HIV-infected infants and young
children is relatively understudied in regions endemic for HIV and TB. We aimed to describe
incidence, clinical features and risk factors of pediatric IRIS in Sub-Saharan Africa and
India.
Methods and findings
We conducted an observational multi-centred prospective clinical study from December
2010 to September 2013 in children <72 months of age recruited from public antiretroviral
programs. The main diagnostic criterion for IRIS was a new or worsening inflammatory
event after initiating antiretroviral therapy (ART). Among 198 participants, median age 1.15
(0.48; 2.21) years, 38 children (18.8%) developed 45 episodes of IRIS. Five participants
(13.2%) had two IRIS events and one (2.6%) had 3 events. Main causes of IRIS were BCG
(n = 21; 46.7%), tuberculosis (n = 10; 22.2%) and dermatological, (n = 8, 17.8%). Four TB
IRIS cases had severe morbidity including 1 fatality. Cytomegalovirus colitis and cryptococ-
cal meningitis IRIS were also severe. BCG IRIS resolved without pharmacological interven-
tion. On multivariate logistic regression, the most important baseline associations with IRIS
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were high HIV viral load (likelihood ratio [LR] 10.629; p = 0.0011), recruitment at 1 site (Stel-
lenbosch University) (LR 4.01; p = 0.0452) and CD4 depletion (LR 3.4; p = 0.0654). Signifi-
cantly more non-IRIS infectious and inflammatory events between days 4 and 17 of ART
initiation were noted in cases versus controls (35% versus 15.2%: p = 0.0007).
Conclusions
IRIS occurs commonly in HIV-infected children initiating ART and occasionally has severe
morbidity. The incidence may be underestimated. Predictive, diagnostic and prognostic bio-
markers are needed.
Introduction
CD4+ T cell depletion from untreated HIV infection predisposes to severe opportunistic and
intercurrent infections [1] [2]. The first evidence that CD4 T cell recovery from antiretroviral
medicines was associated with morbidity came from French et al who described unexpected
Mycobacterium avium-intracellulare disease in immunosuppressed adults after commencing
zidovudine [3]. After combination antiretroviral (ART) was introduced, this phenomenon,
labelled as ‘immune restoration disease’ was increasingly recognized and ascribed to recover-
ing pathogen-specific immunity [4]. Shelburne introduced the term “Immune Reconstitution
Inflammatory Syndrome” (IRIS) recognizing that increased inflammation was a prominent
feature [5]. Two IRIS presentations were recognized: a) “Paradoxical’ for worsening of a
known inflammatory condition and b) “unmasking’ for a previously unrecognized infection
[6].
Although IRIS is reported in children from diverse settings in HIV-infected (HIV+) chil-
dren, only one pediatric prospective study from Thailand, addressed all forms of IRIS [7].
Four studies from Sub-Saharan Africa had prospective data collection. One was cross-sectional
of children initiating ART within the previous two to 24 weeks in Uganda [8]. Another was a
retrospective sub-analysis of IRIS events in the Nevirapine Resistance (NEVEREST) ART
strategy trial [9]. The third addressed BCG IRIS adenopathy from the Children with HIV anti-
retroviral (CHER) trial [10]. Lastly, children with TB disease were followed for paradoxical TB
IRIS once commencing ART [11].
The present study aimed to describe the incidence and clinical features of IRIS in ART-
naïve HIV+ infants and young children where TB is prevalent and neonatal BCG immuniza-
tion is routine. The study was designed to capture baseline clinical data associated with IRIS,
determine the incidence of IRIS, to extend the spectrum of IRIS events, to better document




This prospective, observational clinical study was conducted in 7 clinical research sites: 3 in
South Africa (Stellenbosch University [SU] Cape Town, the Perinatal HIV Research Unit
[PHRU] Soweto and University of KwaZulu-Natal [UKZN] Durban, one each in Zimbabwe
(University of Zimbabwe [UZ], Harare), Tanzania (Kilimanjaro Christian Medical Centre
[KCMC], Moshi) and India (Byramjee Jeejeebhoy Government Medical College [BJMC],
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Pune). The ethics committees of all 7 clinical research sites approved the study and a parent or
legal guardian of each participant gave written informed consent. All sites were in the Interna-
tional Maternal, Pediatric, Adolescent AIDS Clinical Trial (IMPAACT) network. Participants
were recruited from nearby public programs where ART was initiated according to World
Health Organization (WHO) 2010 Guidelines [12] in children with WHO Stage 3 and 4 and
below 2 years of age. CD4 criteria below 5 years of age included a CD4 percentage�25% or
absolute count <750 cells/mm3 and if older, <350 cells/mm3. Antiretroviral dosages were
according to WHO-approved weight bands [12]. In South Africa, all infants below a year of
age were eligible for ART [13].
ART-naïve HIV+ children from 4 weeks to 72 months of age were eligible. If below 12
months of age, BCG immunization was a requirement. Criteria for HIV diagnosis were posi-
tive virological tests from two samples at separate time points, including one from an accred-
ited laboratory. Assays included HIV DNA PCR and plasma HIV RNA above 5000 copies/
mm3. For children above 18 months of age, one assay could be a rapid HIV antibody test.
Malignancy was an exclusion criterion. Maternal and/or paternal written informed consent
and approval by ethics committees from participating sites were required.
The entry study visit was within 7 days preceding ART initiation and at weeks 2, 4, 8, 24
and 48 on ART. After IRIS recognition, additional visits were at weeks 1, 4, 16 and 24 thereaf-
ter. Blood samples for lymphocyte subsets and plasma HIV RNA were collected at enrolment,
weeks 2 and 48 post ART initiation, and for IRIS cases, at all study visits.
Identification and characterization of IRIS
At baseline, participants were examined with documentation of existing and pre-existing con-
ditions. The BCG injection site and regional lymph node sizes were inspected so that changes
suggestive of IRIS would be subsequently recognized. The diagnostic criteria for IRIS were
based on those proposed by Haddow et al (Table 1 and Fig 1) [14]. The most important crite-
rion was onset or worsening of an inflammatory event after ART initiation together with viral
load reduction or CD4 recovery. All new or worsening inflammatory events were evaluated
for IRIS. Site investigators received training on IRIS recognition and were encouraged to sub-
mit descriptions of suspected IRIS events to two investigators (MFC and HR). All clinical
events were documented on case report forms and entered into the IMPAACT database. Also,
clinical events were evaluated at approximately 3 monthly intervals in case IRIS events were
not recognized. Site investigators were then requested to provide more information. An IRIS
Table 1. Criteria for diagnosing paradoxical and unmasking IRIS.
Unmasking IRIS
Clinical criteria
1. Temporal relationship: ART initiation precedes clinical deterioration
2. New onset of symptoms of an infectious or inflammatory condition after initiating ART
3. Consistent with the presence of pre-existing causative pathogen or antigen when starting ART
4. Either of the following:
a. Onset within 3 months after initiating ART
b. Atypical or exaggerated clinical, histological, or radiological findings in terms of severity, character of
inflammatory response, rapidity of onset, or localization
5. Exclusion of other causes
6. Events not explained by:
a. Expected clinical course of another condition
b. Drug toxicity
c. Newly acquired infection, based on clinical history or other evidence
d. Failure of ART: presumptive, based on either nonadherence or resistance to ART, or confirmed, based on VL
assay if available
https://doi.org/10.1371/journal.pone.0211155.t001
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committee, comprising HIV specialists from the protocol team, evaluated all cases to deter-
mine if IRIS was present. The International Network for Study of HIV-associated IRIS
(INSHI) diagnostic criteria were applied retrospectively for TB IRIS [15]. IRIS was designated
paradoxical if an underlying condition was already known and unmasking if a new condition
was identified. Dermatological IRIS was classified as paradoxical if already present at baseline.
For children with baseline TB, an IRIS event ascribed to TB but at a different anatomical site,
was considered ‘site unmasking’. BCG IRIS was considered paradoxical, due to residual M.
bovis-BCG organisms or antigen at the injection site or ipsilateral axillary lymph nodes. Partic-
ipants had study identification numbers (SID). IRIS events were designated as complicated, if
associated with hospitalization or death.
Statistical analysis
Comparisons of baseline characteristics were performed using univariate Wilcoxon and Fish-
er’s Exact tests. Multivariate nominal logistic regression for relationship of IRIS to baseline
characteristics included factors with p-value� 0.05. When considering similar variables, for
example CD4 T-cell count or percentage, the variable with the lowest p-value was selected.
Fig 1. Algorithm for evaluating IRIS events.
https://doi.org/10.1371/journal.pone.0211155.g001
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The degree of association was reported by odds ratios (OR). New onset infectious or inflam-
matory events, not considered IRIS, were documented from day 4 on ART. As all participants
were seen at week 2 and allowing a window of 3 days, the frequency of these events between
days 4 and 17 was compared in those with and without IRIS. For end of study evaluations, chil-
dren completing a minimum of 20 weeks were included. Analysis was done using JMP 14.1,
SAS Corporation. To investigate the relationship between IRIS and other inflammatory or
infectious events, an on-line calculator for Chi-Squares and Fisher’s Exact tabulation was used
(http://www.graphpad.com). We used WHO criteria to exclude outliers for anthropometry Z-
scores. For height for age we excluded Z-score<-5 and>+3; for weight for age we excluded




The study was conducted between December 2010 and September 2013. Nine of 207 partici-
pants were excluded for the following reasons: two parents withdrew consent, two children
received no ART, one was ART-ineligible by concurrent guidelines and 4 participants only
attended the baseline visit. Baseline demographics of the 198 participants evaluated for IRIS
are in Table 2. The majority came from SU (39.6%) and UZ (25.2%). Median age was 1.15
years (0.48–2.21) with 91 participants (45%) below one year of age. Stunting was common
with relatively well-preserved weight for height Z-scores. The majority (61%) had WHO stage
3 or 4 disease. TB was common, 21% having previous TB, 17% receiving anti-TB treatment
and 6% isoniazid prevention therapy (IPT). Twenty-six participants (13%) were receiving cor-
ticosteroids either topically or systemically. CD4 counts and percentages were relatively well
preserved. The majority (85%) had�5 log HIV RNA copies/mm3. The ART regimens are out-
lined in S1 Table. The most common regimen was lopinavir-ritonavir plus abacavir and lami-
vudine (57.6%) followed by nevirapine plus abacavir and lamivudine (25.3%).
IRIS
Thirty-eight participants (18.8%) developed 45 IRIS episodes. Median time to first IRIS event
was 21 days (IQR 13.5 to 55) (range: 4 to 105 days). Sixteen episodes (35.6%) occurred in the
first 14 days of ART and 7 (15.6%) after day 60. Five participants (12%) with baseline
CD4� 25% and 4 (10%) in WHO Stage 1 developed IRIS.
Paradoxical IRIS comprised 71% of IRIS episodes (Fig 2). Of these, most were BCG-related,
(21/46.7% episodes), followed by TB (10/22.2%) and infective or inflammatory skin conditions
(9/26.5%) (Fig 2). Of 6 participants (15.8%) with multiple IRIS events, 5 had 2 events and one
had 3 events (Fig 3). Of these, two had both paradoxical and unmasking events and 4 children
had all either unmasking or paradoxical. Five dermatological or oral IRIS events were diag-
nosed retrospectively after reviewing the clinical data (oral candidiasis, tinea capitis, papular
pruritic eruption, zoster and seborrheic dermatitis) For 42 events from 32 participants,
reviewed retrospectively, we could not diagnose IRIS as were unable to determine whether
there was increased or ‘excessive’ inflammation.
Apart from a child aged 16 months, BCG IRIS occurred in infants below a year of age. Its
spectrum included local injection site reactions, regional axillary adenopathy and both in com-
bination (S2 Table and S1 Fig). Most TB IRIS (7/10) was unmasking and identified at SU (8/
10). (See TB IRIS diagnosis by INSHI criteria in S3 Table) One participant (SID 1228), treated
for pulmonary TB, developed seizures on day 13 due to an unmasked intracerebral tubercu-
loma (S2 Fig).
IRIS in HIV-infected children
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Table 2. Baseline characteristics associated with IRIS.
All No IRIS IRIS Univariate Multivariate logistic regression�
Number 198 160 38




P-value OR (95% CI) P-value OR P-value OR P-
value
Site









1. SU 79 (39.9%) 54 (33.8%) 25 (65.8%)
2. PHRU 19 (9.5%) 19 (11.9%) 0 (0%)
3. UKZN 25 (12.6%) 22 (13.8%) 3 (7.9%)
4. UZ 50 (25.2%) 42 (26.3%) 8 (21.1%)
5. KCMC 20 (2.5%) 19 (11.9%) 1 (2.6%)
6. BJMC 5 (2.5%) 4 (2.5%) 1 (2.6%)
Median (IQR) age
(years)
1.2 (0.5;2.3) 1.3 (0.6;2.3) 0.7 (0.3;1.8 0.0239








Male 104 (52.5%) 82 (51.3%) 22 (57.9%) 0.477
Median (IQR) WAZ -1.65 (-2.89;-
0.65) n = 178
-1.58 (-2.81;-
0.50) n = 144
-1.91 (-3.19;-
1.15) n = 34
0.176
Median (IQR) HAZ -1.54 (-2.28;-
0.64) n = 188
-1.51 (-2.26;-
0.60) n = 154)
-1.80 (-2.47;-
0.84) n = 34
0.284











Stage 1 45 (23%) 41 (25.9%) 4 (10.5%) 0.136
Stage 2∏ 30 (15.3%) 25 (15.8%) 5 (13.2%)
Stage 3 100 (51%) 77 (48.7%) 23 (60.5%)
Stage 4 21 (10.7%) 15 (9.5%) 6 (15.8%)
Stage 1 versus 2,3,4 0.053
TB prior to baseline 42 (21.2%) 28 (17.5%) 14 (36.8%) 0.0141
IPT at baseline 12 (6.1%) 10 (6.3%) 2 (5.26%) 1
Current anti-TB
treatment









1. Any (topical or
systemic)
corticosteroids







2. Systemic only 10 (50.1%) 4 (1.9%) 6 (15.8%) 0.004
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Factors associated with IRIS
On univariate analysis, being recruited at SU, younger age, not WHO stage 1, a history of TB,
receiving anti-TB treatment, receiving topical or systemic corticosteroids, a higher HIV viral
Table 2. (Continued)
All No IRIS IRIS Univariate Multivariate logistic regression�
Number 198 160 38









(Median / IQR) Ø














OR–Odds ratio (�For IRIS = Yes, odds of No versus Yes); P-values for full model on multinomial logistic regression: All IRIS–p <0.0001; paradoxical IRIS–p <0.0001;
unmasking IRIS–p = 0.053
=2 P-values derived from parameter estimates
CI–Confidence interval; IQR–interquartile range; WAZ–weight for age Z-score; HAZ–Height for age Z-score; WHZ–weight for height Z-score; IPT–isoniazid
prevention treatment
# SID 1228 site unmasking TB IRIS
∏ WHO staging not assigned in 2 without IRIS.
Ø 8 plasma HIV RNA levels from baseline unavailable in participants without IRIS.
https://doi.org/10.1371/journal.pone.0211155.t002
Fig 2. Types of paradoxical and unmasking IRIS. In dermatological IRIS, 1 case of Zoster IRIS was considered unmasking. BCG–Bacille Calmette Guérin, TB–
tuberculosis, CMV–cytomegalovirus, CM–cryptococcal meningitis.
https://doi.org/10.1371/journal.pone.0211155.g002
IRIS in HIV-infected children
PLOS ONE | https://doi.org/10.1371/journal.pone.0211155 July 1, 2019 7 / 17
Fig 3. Distribution of IRIS events in participants.
https://doi.org/10.1371/journal.pone.0211155.g003











48 (28.5; 48) 48 (24; 48) 48 (45–49) 0.165
Commenced IPT 3 (1.5%) 2 (1.25%) 1 (2.63%) 0.7
TB
Began TB treatment 15 (7.4%) 6 (3.75%) 9 (23.7%)§ 0.0003�
TB IRIS 6 (15.8%)
Other IRIS (including BCG) 2 (5.3%) 0.17
Death 9 (4.5%) 6 (3.8%) 3 (7.9%) 0.378
Non-IRIS infectious or inflammatory events from day 4 to day 17 40 (20.2%) 24 (15.2%) 14 (35%) 0.0007�
# 4 children lost to follow-up after baseline visit excluded
� Fisher’s exact two-tail test
§ 6 of 9 in IRIS group commencing anti-TB therapy had unmasking TB IRIS; 3 participants had non-TB IRIS events–oral candidiasis; BCG and oral candidiasis; and
CMV colitis
https://doi.org/10.1371/journal.pone.0211155.t003
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load and CD4 depletion were associated with IRIS (Table 2). The ART regimen was not associ-
ated with IRIS (S1 Table)
By multinomial logistic regression, IRIS was most associated with elevated plasma HIV RNA
(LR 10.629; p = 0.0011) and recruitment at SU (LR 4.01p = 0.0452). Low CD4 T-cell count (LR
3.4; p = 0.065) and receiving anti-TB therapy (LR 3.674; p = 0.055) approached significance. For
paradoxical IRIS, plasma HIV RNA was even more strongly associated (LR 12.556; p = 0.0004).
Current TB treatment (LR6.244; p = 0.00125), age below a year (LR 5.559; p = 0.0184) and a
lower CD4+ T-cell count (LR 5.35; p = 0.0207) were also significantly related. For unmasking
IRIS, only being at SU was significantly associated (LR 7.993; p = 0.0047) (Table 2).
Events during study and impact of IRIS on outcomes
Two children were lost to follow-up after two weeks. The median duration for BCG IRIS was
22 weeks (S2 Table). Fifteen participants commenced anti-TB treatment on study, including 6
with unmasking TB IRIS. There was a trend for those with IRIS unrelated to TB to start anti-
TB treatment (p = 0.17) (Table 3). IRIS was implicated in one of three deaths of children with
IRIS (S4 Table). Including the one fatality, 7 participants (18.4%) had severe IRIS (S5 Table).
These included 4 of 10 with TB IRIS. SID 1302 died of progressive paradoxical IRIS. Three par-
ticipants had unmasking TB IRIS: SID 1228 (S2 Table), on anti-TB treatment at baseline had
seizures due to unmasked intracerebral tuberculomas (S2 Fig); SID 1246 developed gall blad-
der destruction, requiring a porto-jejunostomy. For SID 1652, the diagnosis of TB meningitis
was supported by magnetic resonance imaging showing intracerebral granulomas and even-
tual resolution on anti-TB meningitis therapy (S3 Fig). Two participants (SID 1255 and 1282)
developed severe CMV colitis IRIS, one unmasking and one paradoxical, requiring intensive
care support. SID 1303 presenting with inability to walk, required hospitalization for crypto-
coccal meningitis IRIS. Cerebrospinal fluid cryptococcal antigen was detected at initial presen-
tation but not at IRIS diagnosis.
Events at the end of the study in those completing at least 20 weeks on study are shown in
Table 4. During the study, 205 infectious or inflammatory events not considered IRIS were
documented in 101 (51%) children (S4A Fig), mainly dermatological, respiratory and gastroin-
testinal (S4B Fig), 70% noted in the first 60 days. Significantly more events were noted in
Table 4. Anthropometry, CD4 data and HIV viral loads at study end for those completing�20 weeks on study.
N = 170 N = 136 N = 34
WAZ median (IQR) -1.07 (-1.92;-0.09) n = 168 -1.06 (-1.78; -0.07) n = 135 -1.25 (-2.44;-0.44) n = 33 0.28
HAZ median (IQR) 1.31 (-1.94; -0.49) N = 168 -1.31 (-2.11; -0.48) n = 134 -1.35 (-1.81; -0.50) 099
WHZ median (IQR) -0.16 (-1.05; -0.52) n = 166 -0.17 (-1.03;0.50) n = 133 -0.11 (-1.34;0.66) n = 33 0.67
CD4+ % 30.3 (24.1; 36.5) 31 (25.3; 37.9) n = 119 27.4 (20.75; 32.02) n = 34 0.0173
CD4+ cells/mm3 1598 (1195; 2201) 1582 (1168; 2194) 1679 (1366; 2216) 0.49
Plasma HIV-RNA Log10copies/mm
3 1.96 (1.7; 3.1) 1.94 (1.7; 3.09) 2.3 (1.7: 3.67) 0.47
Plasma HIV-RNA <400 copies/mm3 91(53.5%) 101 (64.3%) 28 (68.3%) 0.39
Change between baseline and study end in those�20 weeks on study
WAZ 0.60 (-0.27;1.65) n = 169 0.42(-0.3;1.76) n = 124 0.74(0.17;1.52) 0.27
HAZ 0.25 (-0.17;0.83) n = 159 0.24(-0.22;0.7) n = 128 0.48(0.03;1.31) n = 31 0.087
WHZ 0.42 (-0.57;2.07) n = 153 0.49(-0.56;2.06) n = 122 0.35(-1.07;2.11) n = 31 0.69
CD4+ % 8.5 n = 150 8 (3.13;14) n = 116 9.25 (4.7; 13.63) n = 34 0.90
CD4+ cells/mm3 498 (16.3; 1071) 372 (-17,5; 971) 868 (320; 1352) 0.015
Plasma HIV-RNA Log10copies/mm
3 3.59 (4.22; 2.4) 3.49 (-4.14; -2.38) 4.01 (-4.51; -2.75) 0.052
https://doi.org/10.1371/journal.pone.0211155.t004
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children from SU (65.8%: 52/79) than from other sites (41.2%: 49/119) (p = 0.0006). As IRIS
participants had more visits and more opportunities for documenting intercurrent events, the
comparison was restricted to the first 17 days on ART, when frequency of study visits was the
same. Forty children developed 49 non-IRIS infectious or inflammatory events, significantly
more common in those with IRIS (p = 0.0007) (Table 4) but similar for all sites (SU: (19 / 9.6%
versus 21 / 10.6% from other study sites; p = 0.284).
CD4, viral load and anthropometric measures were assessed in 170 children followed for
20 weeks (Table 4). Anthropometry was similar between those with and without IRIS. The
CD4 percentage in those with IRIS was still significantly below those without IRIS but absolute
CD4+ T cell counts were similar. The CD4+ T cell count increase was significantly higher in
those with IRIS, suggesting greater recovery. There was no difference in virological suppres-
sion although the IRIS group experienced a greater decline in viral load. Participants with IRIS
had a higher increase in height for age Z-score.
IRIS management
Six participants were already receiving prednisone when IRIS was diagnosed. Prednisone was
used to manage severe IRIS in 6 participants, one of whom (SID 1302) died (Table 4). BCG
IRIS was managed conservatively, although two children required pus aspiration for symptom-
atic relief (S2 Table).
Discussion
This is the first multi-centre study of IRIS in infants and young children from Sub-Saharan
Africa and India that prospectively evaluated for both unmasking and paradoxical IRIS. We
confirmed many findings noted individually in other paediatric studies and provided some
new insights [7–9, 17, 18].
Frequency, spectrum and time of onset
Frequency and spectrum of IRIS events were similar to other large pediatric cohort studies
where clinical data was collected prospectively [7–9]. Median time of first IRIS recognition
was 21 days in our study, similar to the NEVEREST and Thai studies [8, 10] and in adults [19].
Earliest time for IRIS in our study was day 4, versus day 7 in NEVEREST and day 14 in Thai-
land [7, 9]. Over 15% of children in our study had more than one IRIS event versus 6.9% of
Thai children [7] and 23.5% from NEVEREST [9]. Time to IRIS onset could not be assessed in
Ugandan pediatric study due to its cross-sectional design [19].
BCG IRIS was most common, followed by TB, dermatological, oral candida, CMV and
cryptococcal meningitis. The highest frequency and co-occurrence of BCG and TB IRIS was
also documented in the NEVEREST study [9]. We found paradoxical IRIS more commonly
than unmasking, most likely due to BCG IRIS being the most common and easily recognized
IRIS. In the cross-sectional Ugandan study, the only other pediatric cohort study to differenti-
ate paradoxical from unmasking IRIS, unmasking IRIS mainly from bacterial pneumonia and
dermatological infections, was three times higher than paradoxical IRIS. This study is limited
by not prospectively documenting existing conditions at baseline. For TB IRIS, both presenta-
tions were equally represented. BCG IRIS comprised only 4.8% of IRIS cases in infants
between 6 and 12 months of age, 10% of this study population. [9] In a large prospective IRIS
study in adults with advanced HIV disease in South Africa, unmasking IRIS, mainly due to
unrecognized TB, was twice as common as paradoxical IRIS [19]. In our study, unmasking TB
IRIS (6 cases) was slightly more common than paradoxical, probably reflecting both active
screening for TB at all of the sites but also the difficulty in diagnosing TB in HIV+ children.
IRIS in HIV-infected children
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In our study, inspection of the BCG injection site and assessing the right axillary lymph
nodes for increased size and tenderness was standard. We provided accurate data on BCG
IRIS, showing that local BCG IRIS was the most common variant (9 of 21: 43%). In compari-
son, in the NEVEREST cohort, local BCG IRIS comprised 12% of BCG IRIS, most likely as
although data were recorded prospectively, IRIS assignation was retrospective [9]. We
described for the first time the median duration of BCG IRIS (22: 10.9–31 weeks), important
for clinicians when counselling parents. BCG IRIS rarely occurs in older children, often associ-
ated with BCG re-immunization [20]. In the CHER trial we reported BCG IRIS adenitis as less
common in infants with high CD4 percentages commencing early ART rather than deferred
until CD4 depletion triggered ART initiation. In a subset of infants with CD4 < 25% begin-
ning early ART, the frequency of BCG IRIS adenitis was similar to the deferred arm [21]. In
the present study, the median age of ART initiation was 21.6 weeks, similar to the deferred
arm of the CHER trial.
For TB-related IRIS, TB was confirmed by culturing drug sensitive Mycobacterium tuberculo-
sis in two cases (20%). In the remainder, diagnosis was based on contact history, suggestive chest
radiographs or brain magnetic resonance imaging, (MRI) and positive Mantoux skin tests.
Unmasking of a brain tuberculoma through new onset seizures, was previously noted in a Cape
Town case series from SU [22]. SID 1652, although diagnosed with TB meningitis IRIS, had little
supporting evidence (S5 Table). Cerebrospinal fluid showed a neutrophil predominance, atypical
for TB meningitis with normal protein and glucose levels. The MRI showed multiple intracere-
bral granulomas with ring-enhancing oedema. This child improved on anti-TB meningitis ther-
apy. One case of unmasking TB IRIS was diagnosed through a strongly positive Mantoux skin
test and the mother’s chest radiograph being compatible with pulmonary TB. This infant devel-
oped progressive biliary obstruction, possibly due to expanding lymph nodes in the porta hepatis
requiring surgical repair and hospitalization for 6 months. Also, we observed paradoxical TB
IRIS in 3 of 33 (9%) with active TB at baseline, more common than the 1.9% (2 of 104) from a
prospective study of children already on anti-TB therapy at ART initiation [11].
In our series, dermatological IRIS comprised 24.5% of events, similar to the older Ugandan
children [8]. Manifestations included papular pruritic eruption, seborrheic dermatitis, zoster
and fungal infections. In the Thai study, the most commonly documented cutaneous IRIS
events were viral, mainly zoster and herpes simplex [7]. In the NEVEREST study, only one
case of seborrheic dermatitis IRIS and one of herpes labialis IRIS were noted (5.9% of IRIS
events). As IRIS was not determined prospectively, dermatological events may have been
missed [9].
We identified two children with CMV-related colitis IRIS, one unmasking and one para-
doxical. CMV colitis IRIS is described in adults [23]. CMV-related IRIS featured prominently
in early adult studies from Australia and the United States [4, 5] but not in Sub-Saharan Africa
[19, 24]. One case of CMV IRIS pneumonitis was identified in the NEVEREST cohort [9]. The
only other descriptions of CMV IRIS in children include two cases of retinitis [25] and one of
fatal myoclonus-opsoclonus and cardiomyopathy from SU, Cape Town [26].
Cryptococcal meningitis, although uncommon, occurs in HIV+ children. [27] Paediatric
cryptococcal IRIS was reported in the Thai study [7] and also in Cape Town [28].
Baseline factors associated with IRIS
IRIS, although more common with advanced HIV disease, was noted in milder HIV infection
[9, 18]. We found, on multinomial analysis, that baseline elevated HIV RNA viral load was sig-
nificantly associated with IRIS. For paradoxical IRIS both baseline elevated HIV RNA and
CD4 depletion were significantly related as already noted for BCG IRIS adenitis in the CHER
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trial [21]. In the 3 main pediatric IRIS cohort studies, CD4 cell depletion rather than viral load
was associated with IRIS on multivariable analysis. In NEVEREST, CD4 depletion and low
WAZ were risk factors on multivariable analysis [9]. Our prospective data confirm the impor-
tance of elevated viral load more so than CD4 depletion being associated with IRIS. In our
study, low WAZ played no role.
Both high viral load and severe CD4 T-cell depletion were associated with paradoxical IRIS
in a South African adult study [19]. In our study, being on current anti-TB therapy was signifi-
cantly associated with paradoxical IRIS, most likely due to paradoxical TB IRIS. Another
explanation is that isoniazid and rifampicin have activity against Mycobacterium bovis-BCG
and might promote antigen release. Van Rie documented a low incidence (5 of 104; 4.8%) of
paradoxical TB IRIS in children with a similar baseline profile to our study. She observed that
some children fulfilling criteria for paradoxical TB IRIS probably had alternative diagnoses
such as bacterial pneumonia as they responded to antibiotic therapy [11].
The topical corticosteroids reflect a high prevalence of dermatitis. Of note, although corti-
costeroids can prevent or ameliorate IRIS in adults, it did not prevent IRIS in our study. In a
recently reported adult study, corticosteroids reduced the incidence of TB IRIS [29].
The only baseline factor associated with unmasking IRIS in our study was enrolment at SU.
We ascribe this to more familiarity with IRIS at SU and proximity to the in-patient setting,
enabling closer monitoring of participants. All children received a baseline chest. From the adult
study from KwaZulu-Natal, associations included C-reactive protein above 25 mg/L, lower hae-
moglobin, more weight loss and radiological evidence of lymphadenopathy. The 2 most com-
mon causes of unmasking IRIS were TB and folliculitis, representing 11% and 19.3% of all IRIS
cases respectively [19]. Both conditions are associated with elevated C-reactive protein [30] [31].
Events during study and impact on IRIS outcomes
Severe morbidity was associated with suspected or confirmed TB IRIS and also CMV, affecting
18% of children with IRIS. Both unmasking and paradoxical TB IRIS had significant morbid-
ity, with the only death related to paradoxical TB IRIS. Except for one retrospective study
which documented severe IRIS morbidity and mortality [32] and isolated case reports, [10, 26]
there has been little data on IRIS severity in children.
We observed a high frequency of intercurrent non-IRIS infectious and inflammatory events
declining over time on ART. Many of these events were considered for IRIS but lacked infor-
mation on the extent of disease and whether exacerbated by ART. Documentation of intercur-
rent events occurred significantly more commonly at SU. However, in the first 17 days on
ART, when all participants had the same number of visits, there was no difference between the
study sites. This finding suggests firstly, that despite our efforts, IRIS events may have been
missed and that multiple IRIS events occur more commonly in those predisposed to IRIS.
That TB treatment was more commonly initiated in those with IRIS is likely due to unmasking
TB IRIS in 6 children. A similar high frequency of intercurrent infections was also observed in
the prospective adult study from KwaZulu-Natal, but was not stratified by IRIS [19].
Although by the end of the study, the CD4 percentage in those with IRIS was still lower
than those without IRIS, the latter had a greater increase in CD4 T-cell numbers. Those with
IRIS had a greater fall in plasma HIV VL but virological suppression to below detectable limits
were the same in those with and without IRIS. Poorer virological response of those with IRIS
in the NEVEREST study was most likely related to rifampicin-induced lowering of lopinavir-
ritonavir exposure [33].
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Management
BCG IRIS was not treated in our study. In earlier studies, anti-mycobacterial therapy was used
often [9, 20]. reducing lopinavir-ritonavir and nevirapine exposure to rifampicin interactions
[34, 35]. Screening for TB in endemic settings before ART initiation should reduce unmasking
TB IRIS, as illustrated in Uganda where a TB screening program was associated with a 70%
decline in incident TB [36]. Although there was high awareness for TB, screening practices
were not uniform in our study and are not very sensitive in HIV-infected children. Many chil-
dren have abnormal chest radiographs in the absence of TB [37]. Tuberculin skin tests are
insensitive and microbiological culture has a low yield in children [38]. This was illustrated by
finding 5 cases of unmasking TB IRIS at SU despite baseline screening.
Limitations of the study
More IRIS cases and more intercurrent infections were identified at one site, most likely due
to increased awareness, the practice of obtaining chest radiographs on all children commenc-
ing ART and close proximity to hospital wards, the latter facilitating regular monitoring of
hospitalized children. That those with IRIS had more infectious or inflammatory events not
regarded as IRIS, suggests that IRIS events were missed. Also, from cases reviewed retrospec-
tively for IRIS, only 5 of 47 infectious or inflammatory events were considered IRIS cases,
because of insufficient supporting data. Our inclusion of these retrospectively determined IRIS
events is another limiting factor. Apart from BCG IRIS, which is easily recognized, IRIS diag-
nosis requires clinical skill. Although training took place, it may have been insufficient. A con-
sideration for future studies is digital image capturing at baseline and thereafter to better
diagnose dermatological and mucosal IRIS events and baseline exclusion of TB, including
chest radiographs. Recognition of CMV IRIS required the availability of CMV viral load
assays, which were not routinely performed even when available at sites.
Relevance of the study
Although the study was completed 5 years ago and HIV guidelines have changed, the potential
for IRIS still remains. Early infant diagnosis guidelines have already shifted from 6 weeks of age to
birth, with the potential to begin ART much earlier. Point of care HIV diagnosis will facilitate
early diagnosis but must still be established in non-research settings. Also, despite progress in
reducing vertical transmission, 160,000 newly infected infants were born in 2016. Vertical trans-
mission during breast feeding remains an ongoing risk, with a high likelihood of late diagnosis
[39]. We had previously noted that the majority of HIV+ infants already have advanced HIV dis-
ease by 12 weeks of age in a public program [40]. IRIS can also occur in children with asymptom-
atic HIV disease and high CD4 counts, as noted in our study. Although most ART regimens in
our study are still widely used, the integrase strand inhibitors are being introduced and will
become an important component of ART. Recent cohort studies suggest a higher rate of IRIS due
to more rapid viral load reduction, [41] but this was not born out in a randomized study [42].
Conclusions
IRIS occurs commonly in HIV-infected infants and young children. It is commonly, but not
exclusively, seen in those with advanced HIV disease. Adequate screening for TB and CMV
infection is essential to minimise unmasking IRIS. Although often benign and self-limiting,
the consequences of IRIS can be severe. A better understanding of pathogenesis and identifica-
tion of biomarkers to predict IRIS risk and assist diagnosis are needed.
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